Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
about
Medical interventions for primary open angle glaucoma and ocular hypertensionCombination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focusGlaucoma: a review of adjunctive therapy and new management strategies.Considerations in glaucoma therapy: fixed combinations versus their component medications.Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis.Clinical options for the reduction of elevated intraocular pressureThe impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies.Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure.Effect of topical anti-glaucoma medications on late pupillary light reflex, as evaluated by pupillometry.Twenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed combination in primary open-angle glaucoma.The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studiesPreliminary results following the use of a fixed combination of timolol-brimonidine in patients with ocular hypertension and primary open-angle glaucomaPhase III safety and efficacy study of long-term brinzolamide/timolol fixed combination in Japanese patients with open-angle glaucoma or ocular hypertension.Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma.Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.Brimonidine for glaucoma.Role of fixed combinations in the management of open-angle glaucoma.Emerging drugs for ocular hypertension.Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye.Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.Challenging issues in molecular-targeted therapy.Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost.Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension.Brimonidine promotes axon growth after optic nerve injury through Erk phosphorylation.Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension.Comparison of brimonidine-timolol and dorzolamide-timolol in the management of intraocular pressure increase after phacoemulsification.A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure.Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.Effects of 0.2% brimonidine and 0.2% brimonidine-0.5% timolol on intraocular pressure and pupil size in normal equine eyes.Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma.Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients.
P2860
Q24243220-2156B83D-7E8A-4C66-9BCC-6C44FD2BEB34Q26830201-F586F056-D13F-4E11-A916-D2670F29E4CEQ33307040-78988621-291E-4ACA-9DF6-2E96CEB5E4ACQ33644139-5D56DD9E-6A31-4D61-8294-BAC93575093EQ34428023-6FFBAD2A-EC44-4A9B-9894-21D43EC90EC6Q34708267-0EBAB28E-42EC-4AC3-AE9C-908F0F09536EQ34731426-C6C5A574-2746-4A41-88C6-BA989DFA307DQ34981291-D16B9885-3484-4D9B-9D3F-2CE50EFA0CA5Q34996623-E7AA84F5-125F-4715-939D-74FAF5454283Q35550289-B42CB7A4-96AE-4E7B-9C9D-0D666D8F051FQ35676220-8AEC4BB7-D27B-498B-A82A-8534F6DDBE73Q37106339-53E87D4A-6A73-4173-9F68-257F7EB7492DQ37257696-FD51F1BB-DDC8-45F7-B353-0F08FB15E75CQ37444622-A3F2694C-69AE-45BB-866B-155C1FC09E1FQ37566607-56C9C978-D75C-47EB-B92D-D2F754FC9BA1Q37716010-909F7448-90D4-4636-8B4A-7911C81A100BQ37724357-293C4C8E-FBE2-4C0E-9DEA-115E797ABD27Q37847155-5F6C0DE4-CC16-4F70-AF23-4FE1ABEBCAF0Q37847182-A9764916-6291-45CF-9752-69E61636EB60Q38065980-A03343E0-8675-41FC-98AE-1329D02ACF71Q38226662-28BE3563-E213-4D87-9D8D-573E4769B67CQ41436013-92E69F01-B53D-4679-8496-34D347B30257Q41823074-BBAA4083-E179-41ED-9E8C-7B6DC9DDCA50Q41877762-231A0F6C-325D-497D-95AA-3BD0A5636818Q42009144-BE6844A1-26D2-4632-A145-8BC8181BB1D8Q42075577-D3549A2B-F666-4FD2-8449-A5542EFCFA3EQ43191011-B99B8358-9F2F-402F-96AF-084093BFE850Q45462727-34E1F6D6-A1FE-4572-B082-C8AFF6ECC60FQ46154462-64A379E9-E4DA-4DDD-B6EB-23C319718156Q46315630-CC7BF0D5-0DE8-4BBE-B36B-25CD0195B4F2Q46644724-E7700BAA-1C97-410F-B5A6-60C787E8F77CQ53185340-C69C5345-7D37-4B88-88B7-CB68194C65EE
P2860
Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Twice-daily 0.2% brimonidine-0 ...... : a 12-month randomized trial.
@ast
Twice-daily 0.2% brimonidine-0 ...... : a 12-month randomized trial.
@en
Twice-daily 0.2% brimonidine-0 ...... : a 12-month randomized trial.
@nl
type
label
Twice-daily 0.2% brimonidine-0 ...... : a 12-month randomized trial.
@ast
Twice-daily 0.2% brimonidine-0 ...... : a 12-month randomized trial.
@en
Twice-daily 0.2% brimonidine-0 ...... : a 12-month randomized trial.
@nl
prefLabel
Twice-daily 0.2% brimonidine-0 ...... : a 12-month randomized trial.
@ast
Twice-daily 0.2% brimonidine-0 ...... : a 12-month randomized trial.
@en
Twice-daily 0.2% brimonidine-0 ...... : a 12-month randomized trial.
@nl
P2093
P1433
P1476
Twice-daily 0.2% brimonidine-0 ...... n: a 12-month randomized trial
@en
P2093
Amy L Batoosingh
Connie Chou
Harvey B DuBiner
Mark B Sherwood
Rhett M Schiffman
P304
P356
10.1001/ARCHOPHT.124.9.1230
P407
P577
2006-09-01T00:00:00Z